APLS Company Profile and Key Details

Q: Who are the executives of APLS?

Dr. Federico Grossi M.D., Ph.D.Co-Founder & Chief Medical OfficerMr. Timothy E. SullivanChief Financial Officer & TreasurerDr. Pascal Deschatelets Ph.D.Co-Founder & Chief Scientific OfficerMr. Alec Machiels J.D., MBACo-Founder & DirectorMs. Meredith KayaSenior Vice President, Investor Relations & Strategic Fin.Mr. James G. Chopas CPAVice President, Corporation Controller & Chief Accounting OfficerMr. David O. Watson Esq., J.D.Gen. CounselMs. Nur NicholsonChief Technical Operations OfficerMr. Adam J. TownsendChief Commercial OfficerMs. Karen LewisChief People OfficerDr. Cedric Francois M.D., Ph.D.Co-Founder, Pres, Chief Executive Officer & Director

NASDAQ : APLS

Apellis Pharmaceuticals

$40.86

0.01+0.02%

Open: 1:25 PM

70.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Apellis Pharmaceuticals, Inc. (APLS) stock surged +0.02%, trading at $40.86 on NASDAQ, up from the previous close of $40.85. The stock opened at $40.84, fluctuating between $40.84 and $40.88 in the recent session.

Stock Snapshot

40.845

Prev. Close

5.22B

Market Cap

40.84

Day Low

226.97

P/E Ratio

0.18

EPS (TTM)

-4.91

Cash Flow per Share

40.84

Open

127.83M

Number of Shares

40.88

Day High

82.62%

Free Float in %

1.6

Book Value

1.65M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	40.85	40.88	40.78	40.85	4.52M
Apr 13, 2026	40.73	40.87	40.70	40.84	5.83M
Apr 10, 2026	40.67	40.79	40.65	40.79	6.74M
Apr 09, 2026	40.74	40.76	40.64	40.65	7.06M
Apr 08, 2026	40.66	40.74	40.65	40.69	4.58M
Apr 07, 2026	40.61	40.77	40.60	40.70	4.3M
Apr 06, 2026	40.43	40.69	40.41	40.63	6.08M
Apr 02, 2026	40.37	40.48	40.35	40.41	10.33M
Apr 01, 2026	40.35	40.42	40.32	40.39	28.76M
Mar 31, 2026	40.40	40.45	40.22	40.23	90.33M
Mar 30, 2026	16.98	17.27	16.83	17.09	2.16M
Mar 27, 2026	17.55	17.61	16.97	16.97	1.76M
Mar 25, 2026	17.44	17.96	17.39	17.72	1.87M
Mar 24, 2026	17.46	17.46	16.84	17.23	2.14M
Mar 23, 2026	17.60	17.94	17.32	17.57	2.41M
Mar 20, 2026	17.96	18.09	17.16	17.21	5.6M
Mar 19, 2026	17.89	18.01	17.57	17.97	2.33M
Mar 18, 2026	18.43	18.59	17.43	17.89	5.25M
Mar 17, 2026	18.94	19.32	18.74	18.82	1.34M
Mar 16, 2026	19.10	19.36	18.77	18.87	1.33M

Contact Details

Waltham, MA 02451

United States

https://www.apellis.com 617 977 5700

About Company

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Stock Peers

ARGX

19.08+2.36%

argenx SE$828.35 REGN

9.05+1.21%

Regeneron Pharmaceuticals, Inc.$755.51 UTHR

0.91+0.16%

United Therapeutics Corporation$578.54 MDGL

-0.68-0.13%

Madrigal Pharmaceuticals, Inc.$524.99 VRTX

4.23+0.96%

Vertex Pharmaceuticals Incorporated$444.28 PRAX

26.6+8.39%

Praxis Precision Medicines, Inc.$343.60 ALNY

6.41+1.92%

Alnylam Pharmaceuticals, Inc.$339.41 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.59+0.97%

Krystal Biotech, Inc.$270.00 ASND

1.29+0.52%

Ascendis Pharma A/S$249.84

Company Overview

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) closed at $40.85 USD, gaining $0.01 (0.02%) from the previous close of $40.84. The stock is currently trading near its 52-week high $16.10 and $40.88. With a market capitalization of about $5.22 billion, Apellis Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.20). Key stats such as the average daily volume over the past year has been around 5.10 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Apellis Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cedric Francois, the company employs approximately 705 people and listed since November 09, 2017. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

Technical Performance

APLS has shown weak momentum, losing -11.77% over the past week and -16.52% over the past quarter, though year-to-date performance is down -18.51%. Short-term trend indicators are mixed aligned (SMA20 -3.6%, SMA50 -6.81%, SMA200 -3.13%). The stock’s 14-day RSI is 44.0 (neutral), while the ATR of 1.2 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.0% below its high and over 34.41% above its low. Average 10-day trading volume of 5.59 million shares is in line with the 3-month average of 5.13 million, indicating normal recent market interest.

Valuation Metrics

Apellis Pharmaceuticals, Inc. trades at a P/E ratio of 229.98, slightly above the S&P 500 average, with a price-to-sales ratio of 5.2 and a price-to-book ratio of 13.91 reflecting a rich premium to book value. The P/FCF stands at 115.22, also above market averages. Compared to sector medians, Apellis Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Apellis Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$34.58. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 61.57% annually over the next five years. The latest quarter delivered EPS of $1.67. The next quarter is forecast at -$0.35. Next year's EPS is expected at $61.45. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 13 Buy ratings, 13 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $18.00. The high target offers 34.64% upside. The low target suggests -55.94% downside. The mean target is $35.82. This offers -12.31% upside. Apellis Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by 62.14%.

Shareholding & Insider Activity

Apellis Pharmaceuticals, Inc. has 127.84 million shares outstanding. The public float is 83.25 million shares, elevated short interest at 23.54% of float. This equals 22.93 million shares. The short ratio is 11.43 days. Institutional investors hold 120.35% of the float. Insiders own 13.64%. Deschatelets Pascal holds 1.15 million shares, Machiels Alec has 367.42 thousand shares and Francois Cedric has 286.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 143.56 thousand shares across 29 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Apellis Pharmaceuticals generated $396.59M in revenue, or $3.34 per share. Gross margin was 84.82%, operating margin -130.39%, and net profit margin -133.29%. Returns are negative, with ROA at -67.02% and ROE at -271.76%.
On valuation metrics, Apellis Pharmaceuticals trades at a P/E of 229.98, P/S of 5.20 and P/B of 13.91. The current ratio is 3.14 and quick ratio is 2.70. Operationally, the company’s inventory turnover is 0.72 and cash conversion cycle is 438.01 days. Debt-to-equity is 1.31, supported by a cash flow-to-debt ratio of 0.09.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Apellis Pharmaceuticals posted revenue of $396.59M, down slightly from $75.42M in the prior quarter. Gross profit was $336.38M (margin 84.82%). Operating income was - $517.12M (margin -130.4%). Net income was- $528.63M (EPS - $4.45).
The company ended the quarter with $352.30M in cash and short-term investments, a total debt of $110.93M, and net debt of - $241.37M. Total assets were $788.73M, with equity of $194.52M. Financials further reflected weakness, with operating cash flow of - $594.74M, free cash flow of - $595.51M, and capital expenditures of - $773.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Apellis Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 16.18%, with price expected at $47.46 by April 28, 2026, within a range of $38.75 to $56.64 3-Month Outlook: Projected rise of 106.12%, reaching $84.20 by July 13, 2026, with a range of $82.71 to $87.61. 1-Year Outlook: Projected loss of -64.75%, with price at $14.40 by April 14, 2027, within a range of $10.06 to $19.25.

Key Takeaways

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are down -18.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Apellis Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 229.98. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $58.82, suggesting 43.99% upside. Our AI forecast model points to short-term strength (16.18% over two weeks), a medium-term rise (106.12% over three months), and a longer-term loss (-64.75% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Apellis Pharmaceuticals, Inc. (APLS) stock price?

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock price is $40.86 in the last trading session. During the trading session, APLS stock reached the peak price of $40.88 while $40.84 was the lowest point it dropped to. The percentage change in APLS stock occurred in the recent session was 0.02% while the dollar amount for the price change in APLS stock was $0.01.

APLS's industry and sector of operation?

The NASDAQ listed APLS is part of Biotechnology industry that operates in the broader Healthcare sector. Apellis Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of APLS?

Dr. Federico Grossi M.D., Ph.D.
Co-Founder & Chief Medical Officer
Mr. Timothy E. Sullivan
Chief Financial Officer & Treasurer
Dr. Pascal Deschatelets Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Alec Machiels J.D., MBA
Co-Founder & Director
Ms. Meredith Kaya
Senior Vice President, Investor Relations & Strategic Fin.
Mr. James G. Chopas CPA
Vice President, Corporation Controller & Chief Accounting Officer
Mr. David O. Watson Esq., J.D.
Gen. Counsel
Ms. Nur Nicholson
Chief Technical Operations Officer
Mr. Adam J. Townsend
Chief Commercial Officer
Ms. Karen Lewis
Chief People Officer
Dr. Cedric Francois M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director

How APLS did perform over past 52-week?

APLS's closing price is 153.73% higher than its 52-week low of $16.10 where as its distance from 52-week high of $40.88 is -0.06%.

How many employees does APLS have?

Number of APLS employees currently stands at 705.

Link for APLS official website?

Official Website of APLS is: https://www.apellis.com

How do I contact APLS?

APLS could be contacted at phone 617 977 5700 and can also be accessed through its website. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, United States.

How many shares of APLS are traded daily?

APLS stock volume for the day was 1.65M shares. The average number of APLS shares traded daily for last 3 months was 5.1M.

What is the market cap of APLS currently?

The market value of APLS currently stands at $5.22B with its latest stock price at $40.86 and 127.83M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	705
Beta	0.29
Sales or Revenue	$396.59M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

APLS Company Profile and Key Details

Apellis Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways